Detalhe da pesquisa
1.
Prevention efficacy of the broadly neutralizing antibody VRC01 depends on HIV-1 envelope sequence features.
Proc Natl Acad Sci U S A
; 121(4): e2308942121, 2024 Jan 23.
Artigo
Inglês
| MEDLINE | ID: mdl-38241441
2.
Neutralization profiles of HIV-1 viruses from the VRC01 Antibody Mediated Prevention (AMP) trials.
PLoS Pathog
; 19(6): e1011469, 2023 06.
Artigo
Inglês
| MEDLINE | ID: mdl-37384759
3.
Structure and Recognition of a Novel HIV-1 gp120-gp41 Interface Antibody that Caused MPER Exposure through Viral Escape.
PLoS Pathog
; 13(1): e1006074, 2017 01.
Artigo
Inglês
| MEDLINE | ID: mdl-28076415
4.
Replication Capacity of Viruses from Acute Infection Drives HIV-1 Disease Progression.
J Virol
; 91(8)2017 04 15.
Artigo
Inglês
| MEDLINE | ID: mdl-28148791
5.
Combining Viral Genetics and Statistical Modeling to Improve HIV-1 Time-of-infection Estimation towards Enhanced Vaccine Efficacy Assessment.
Viruses
; 11(7)2019 07 03.
Artigo
Inglês
| MEDLINE | ID: mdl-31277299
6.
Early evolution of human leucocyte antigen-associated escape mutations in variable Gag proteins predicts CD4+ decline in HIV-1 subtype C-infected women.
AIDS
; 31(2): 191-197, 2017 01 14.
Artigo
Inglês
| MEDLINE | ID: mdl-27755110
7.
Brief Report: Selection of HIV-1 Variants With Higher Transmission Potential by 1% Tenofovir Gel Microbicide.
J Acquir Immune Defic Syndr
; 76(1): 43-47, 2017 09 01.
Artigo
Inglês
| MEDLINE | ID: mdl-28797020
8.
No evidence for selection of HIV-1 with enhanced gag-protease or Nef function among breakthrough infections in the CAPRISA 004 tenofovir microbicide trial.
PLoS One
; 8(8): e71758, 2013.
Artigo
Inglês
| MEDLINE | ID: mdl-24015191